MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.240
-0.060
-1.82%
After Hours: 3.200 -0.04 -1.23% 17:24 10/20 EDT
OPEN
3.360
PREV CLOSE
3.300
HIGH
3.400
LOW
3.120
VOLUME
715.22K
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.6200
MARKET CAP
238.84M
P/E (TTM)
-4.6312
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Galapagos Knee Osteoarthritis Data, And Other News: The Good, Bad And Ugly Of Biopharma
Galapagos announces topline data from knee osteoarthritis trial. Evelo provides updates for EDP1815 in Atopic Dermatitis and Psoriasis trials. CTI BioPharma initiates NDA process for Pacritinib.
Seekingalpha · 2d ago
CTI BioPharma begin rolling submission for pacritinib in myelofibrosis in US
CTI BioPharma (CTIC) +4% in premarket, on commencement of a rolling market application submission to the FDA seeking approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (characterized by low levels
Seekingalpha · 10/13 12:42
The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
Benzinga · 10/07 11:30
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
Benzinga · 10/06 12:24
MYOK, TEF among premarket gainers
MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals
Seekingalpha · 10/05 12:28
Aduro Biotech, American Renal Associates leads healthcare gainers; Benitec Biopharma, Mesoblast among major losers
Gainers: Aduro Biotech (ADRO) +442%, American Renal Associates (ARA) +69%, Nano-X Imaging (NNOX) +38%, CTI BioPharma (CTIC) +18%, ProPhase Labs (PRPH) +16%.Losers: Benitec Biopharma (BNTC) -36%, Mesoblast (MESO) -36%, Arcutis Biotherapeutics (ARQT) -14%, PDL BioPharma (PDLI) -13%, Electromed (ELMD) -12%.
Seekingalpha · 10/02 14:56
CTI BioPharma (CTIC) Stock Could Hit $6, Says Analyst
Until yesterday, shares of CTI BioPharma (CTIC) had been firmly planted in the red in 2020. But sentiment can turn fast in the biotech world and the cancer drug maker provided investors with a dreamy week. The stock surged 135% over the past two trading sessions, after the FDA cleared the way for one
TipRanks · 10/01 22:52
The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)
Benzinga · 10/01 12:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTIC. Analyze the recent business situations of CTi Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTIC stock price target is 6.00 with a high estimate of 8.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 76
Institutional Holdings: 36.05M
% Owned: 48.91%
Shares Outstanding: 73.72M
TypeInstitutionsShares
Increased
9
239.44K
New
12
23.46K
Decreased
10
2.42M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.90%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/Director/
Laurent Fischer
President/Chief Executive Officer/Director/
Adam Craig
Chief Financial Officer/Executive Vice President/
David Kirske
Chief Operating Officer/
Bruce Seeley
Executive Vice President/Chief Scientific Officer/
Jack Singer
Senior Vice President/
Nancy Boman
Senior Vice President/
Monique Greer
Director/
Michael Metzger
Director/
Matthew Perry
Independent Director/
David Parkinson
Independent Director/
Frederick Telling
Independent Director/
Reed Tuckson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CTIC
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.